Todd M Bauer

Todd M Bauer

UNVERIFIED PROFILE

Are you Todd M Bauer?   Register this Author

Register author
Todd M Bauer

Todd M Bauer

Publications by authors named "Todd M Bauer"

Are you Todd M Bauer?   Register this Author

39Publications

1412Reads

44Profile Views

Clinical Management of Adverse Events Associated with Lorlatinib.

Oncologist 2019 Aug 19;24(8):1103-1110. Epub 2019 Mar 19.

Massachusetts General Hospital, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2018-0380DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693708PMC
August 2019

Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study.

Invest New Drugs 2019 Jul 13. Epub 2019 Jul 13.

Department of Pharmacy, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-019-00835-yDOI Listing
July 2019

First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.

J Clin Oncol 2018 11 4;36(33):3298-3306. Epub 2018 Oct 4.

John H. Strickler, Duke University Medical Center, Durham, NC; Colin D. Weekes, University of Colorado, Aurora, CO; John Nemunaitis, Mary Crowley Cancer Research Center, Dallas, TX; Ramesh K. Ramanathan, Virginia Piper Cancer Center at Honor Health/Translational Genomics Research Institute, Scottsdale, AZ; Rebecca S. Heist, Massachusetts General Hospital Cancer Center, Boston, MA; Daniel Morgensztern, Washington University School of Medicine, St. Louis, MO; Eric Angevin, Gustave Roussy, Villejuif, France; Todd M. Bauer, Sarah Cannon Research Institute; Todd M. Bauer, Tennessee Oncology, Nashville, TN; Huibin Yue, Daniel Afar, and Louie Naumovski, AbbVie Inc.; Apurvasena Parikh, Clinical Pharmacology and Pharmacometrics, AbbVie Inc., Redwood City; Karen Kelly, University of California Davis Comprehensive Cancer Center, Sacramento, CA; and Monica Motwani, Edward B. Reilly, AbbVie Inc., North Chicago, IL.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2018.78.7697
Publisher Site
http://dx.doi.org/10.1200/JCO.2018.78.7697DOI Listing
November 2018

Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037).

J Clin Oncol 2018 Sep 28:JCO2018789602. Epub 2018 Sep 28.

Tara C. Mitchell, University of Pennsylvania; Anthony J. Olszanski, Fox Chase Cancer Center, Philadelphia, PA; Omid Hamid and Ani S. Balmanoukian, The Angeles Clinic and Research Institute, Los Angeles, CA; David C. Smith, University of Michigan, Ann Arbor, MI; Todd M. Bauer, Tennessee Oncology, Nashville, TN; Jeffrey S. Wasser, University of Connecticut School of Medicine, Farmington, CT; Jason J. Luke and Thomas F. Gajewski, University of Chicago Medicine, Chicago, IL; Emmett V. Schmidt, Merck & Co, Kenilworth, NJ; and Yufan Zhao, Xiaohua Gong, Janet Maleski, and Lance Leopold, Incyte Corporation, Wilmington, DE.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.9602DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225502PMC
September 2018

A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer.

Clin Cancer Res 2018 07 10;24(14):3253-3262. Epub 2018 Apr 10.

Stephenson Oklahoma Cancer Center/Sarah Cannon Research Institute, Oklahoma City, Oklahoma.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-3421DOI Listing
July 2018

Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies.

Invest New Drugs 2018 04 18;36(2):240-247. Epub 2017 Aug 18.

Quantitative Clinical Pharmacology, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-017-0498-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5869873PMC
April 2018

A Phase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumors.

Onco Targets Ther 2018 30;11:2399-2407. Epub 2018 Apr 30.

Department of Medicine, Duke University Medical Center, Durham, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S157331DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935192PMC
April 2018

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.

J Clin Oncol 2017 Apr 28;35(10):1112-1118. Epub 2016 Dec 28.

Kathleen N. Moore, University of Oklahoma Health Sciences Center, Oklahoma City, OK; Lainie P. Martin, Fox Chase Cancer Center, Philadelphia, PA; David M. O'Malley, Ohio State University James Cancer Center, Columbus, OH; Ursula A. Matulonis, Dana-Farber Cancer Institute; Michael J. Birrer, Massachusetts General Hospital, Boston; Rodrigo Ruiz-Soto, ImmunoGen, Waltham, MA; Jason A. Konner, Memorial Sloan Kettering Cancer Center, New York, NY; Raymond P. Perez, University of Kansas, Fairway, KS; and Todd M. Bauer, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.9538DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559878PMC
April 2017

Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors.

J Clin Oncol 2016 10;34(29):3562-3569

Aung Naing, Rivka R. Colen, David S. Hong, and Nizar M. Tannir, MD Anderson Cancer Center, Houston; Kyriakos P. Papadopoulos and Drew R. Rasco, START Center for Cancer Care, San Antonio, TX; Karen A. Autio, Memorial Sloan Kettering Cancer Center, New York, NY; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Manish R. Patel, Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Deborah J. Wong, University of California Los Angeles, Los Angeles; Melinda Whiteside, John B. Mumm, Ivan H. Chan, Peter Van Vlasselaer, and Martin Oft, ARMO BioSciences, Redwood City, CA; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Shubham Pant, Oklahoma University, Oklahoma City, OK; and Johanna C. Bendell, Todd M. Bauer, and Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.1106DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5657013PMC
October 2016

Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer.

J Clin Oncol 2016 05 4;34(15):1764-71. Epub 2016 Apr 4.

David Hong, Filip Janku, Ly M. Nguyen, Aung Naing, Sarina Piha-Paul, Faye M. Johnson, and Razelle Kurzrock, The University of Texas MD Anderson Cancer Center, Houston, TX; Jeffrey Infante, Suzanne Jones, Howard Burris, Todd M. Bauer, and Johanna Bendell, Sarah Cannon Research Institute; Jeffrey Infante, Howard Burris, Todd M. Bauer, and Johanna Bendell, Tennessee Oncology, Nashville, TN; and Lisa Golden, Scott Hynes, Ji Lin, and Aimee Bence Lin, Eli Lilly, Indianapolis, IN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.5788DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321045PMC
May 2016

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.

J Thorac Oncol 2015 Dec;10(12):1670-4

*Department of Medicine, Massachusetts General Hospital, Boston, MA; †Department of Pathology, Massachusetts General Hospital, Boston, MA; ‡Memorial Sloan Kettering Cancer Center, New York, NY; ‖Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; §Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; ¶Department of Medicine, Georgetown University Medical Center, Washington, DC; #University of California Irving Health, Orange, CA; **Dana-Farber Cancer Institute, Boston, MA; ††Beth Israel Deaconess Medical Center, Boston, MA; and ‡‡Ignyta, Inc., San Diego, CA.

View Article

Download full-text PDF

Source
http://ignyta.com/wp-content/uploads/2016/01/Durable-Clinica
Web Search
http://linkinghub.elsevier.com/retrieve/pii/S155608641535087
Publisher Site
http://dx.doi.org/10.1097/01.JTO.0000473485.38553.f0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643748PMC
December 2015

Targeting PI3 kinase in cancer.

Pharmacol Ther 2015 Feb 18;146:53-60. Epub 2014 Sep 18.

Sarah Cannon Research Institute, Nashville, TN, USA; Tennessee Oncology, PLLC, Nashville, TN, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pharmthera.2014.09.006DOI Listing
February 2015

A 17 year-old man with an exon 11 mutation of CD-117 causing a gastrointestinal stromal tumor.

Cancer Invest 2008 Mar;26(2):182-4

Department of Internal Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, Tennessee 37232-6307, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/07357900701637824DOI Listing
March 2008